Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805.
No abstract available

Publication types

  • Published Erratum